plerixafor has been researched along with Diabetic Nephropathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Advani, A; Advani, SL; Alghamdi, TA; Batchu, SN; Chen, LH; Connelly, KA; Gibson, IW; Marsden, PA; Siddiqi, FS; Sood, MM; Thai, K; White, KE | 1 |
| Drucker, DJ; Fujishima, H; Fujita, H; Morii, T; Narita, T; Sato, T; Seino, Y; Shimizu, T; Takahashi, T; Takashima, S; Tsukiyama, K; Yamada, Y | 1 |
2 other study(ies) available for plerixafor and Diabetic Nephropathies
| Article | Year |
|---|---|
CXCR4 promotes renal tubular cell survival in male diabetic rats: implications for ligand inactivation in the human kidney.
Topics: Albuminuria; Animals; Benzylamines; Cell Survival; Chemokine CXCL12; Cyclams; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epithelial Cells; Gene Expression Regulation; Heterocyclic Compounds; Humans; Kidney Tubules; Male; Matrix Metalloproteinase 9; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats; Real-Time Polymerase Chain Reaction; Receptors, CXCR; Receptors, CXCR4 | 2015 |
Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy.
Topics: Albuminuria; Animals; Benzylamines; Chemokine CXCL12; Cyclams; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Female; Fibrosis; Glomerular Filtration Rate; Glucagon-Like Peptide-1 Receptor; Heterocyclic Compounds; Humans; Hypoglycemic Agents; Kidney; Linagliptin; Liraglutide; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Receptors, CXCR4; Up-Regulation | 2016 |